Saizen® (r-hGH) immunogenicity assessed in adult Growth Hormone Deficiency patients

Growth Hormone Deficiency (GHD) in adults leads to various health issues, including altered body composition, reduced bone mineral density, and impaired quality of life. Recombinant human growth hormone (r-hGH) therapy, such as Saizen®, is the standard treatment to replace endogenous GH. However, as a protein therapeutic, r-hGH can induce an immune response, leading to the formation of anti-drug antibodies. These antibodies may neutralize the therapeutic effect or cause adverse reactions. Understanding the immunogenicity of Saizen® is crucial for optimizing long-term treatment outcomes and patient safety in GHD management.

This study's primary objective was to assess the immunogenicity of Saizen® solution for injection in adult subjects diagnosed with Growth Hormone Deficiency (GHD). The abstract, however, does not provide specific methodological details such as the total number of participants, the exact Saizen® dosing regimen, route of administration, or the duration of treatment. Furthermore, the specific assays (ELISA, radioimmunoassay, neutralizing antibody assay) employed to detect and characterize anti-drug antibodies were not described. The study aimed to characterize the immune response to Saizen® in this patient population, but the protocol specifics remain undisclosed in this summary.

The provided abstract outlines the study's objective to assess the immunogenicity of Saizen® in adult GHD patients but does not include any specific findings or numerical results. Therefore, no data on antibody incidence, titers, or their clinical significance can be reported from this abstract. The study's completion status (NCT02507245) suggests data may exist, but they are not presented here.